Aspirin vs Clopidogrel for Long-Term Maintenance After Coronary Stenting in Patients With Diabetes
JAMA Cardiology
TAKE-HOME MESSAGE
This post hoc analysis of the HOST-EXAM trial assessed the effect of clopidogrel versus aspirin on mortality and recurrent cardiovascular events in patients with and without diabetes who recently underwent percutaneous coronary intervention.
The risk of all-cause death, myocardial infarction, and stroke was lower in the clopidogrel monotherapy group than in the aspirin monotherapy group (HR, 0.69; 95% CI, 0.49–0.96). This association did not change when comparing patients with and without diabetes. The risk for any bleeding was also comparable between patients with and without diabetes.

Clopidogrel monotherapy may be associated with improved outcomes in patients who completed a course of dual antiplatelet therapy, irrespective of diabetes status.

G Mohan